1. Once Unilife sign the Exclusivity List with Sanofi (pending, due now) they will then be able to enter into agreements with other pharmaceutical companies for the Unifill syringes.
2. The company has said that they are in talks with other pharmaceutical companies already, with Jim even dropping a line at the EGM that Alan was off to see another pharma after a meeting with Sanofi.
I consider the above to be pretty major as it opens up the gate to receiving Access Fee's from additional pharma. The anticipation itself of a new customer could keep a solid base to the price, couple that with actual liquidity on the Nasdaq (computershare getting act together) and we could see upward pressure applied. Let's also not forget our little 1ml:)
Just my thoughts...........
UNS Price at posting:
$1.29 Sentiment: Buy Disclosure: Held